Promising cancer drug tarlatamab tested in new tumor types

NCT ID NCT06788938

First seen Feb 01, 2026 · Last updated May 02, 2026 · Updated 17 times

Summary

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with advanced DLL3-expressing cancers will receive tarlatamab and be monitored for response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UC Davis Comprehensive Cancer Center

    RECRUITING

    Davis, California, 95817, United States

    Contact Email: •••••@•••••

    Contact

  • UC San Diego Moores Cancer Center

    RECRUITING

    San Diego, California, 92093, United States

    Contact Email: •••••@•••••

    Contact

  • UCI Health Chao Family Comprehensive Cancer Center

    RECRUITING

    Irvine, California, 92612, United States

    Contact

    Contact Email: •••••@•••••

  • University of California at Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of California at San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.